Treatment With Oral Propranolol for Refractory Classic Cutaneous Kaposi Sarcoma

Affiliations

¹ Department of Dermatology, University Clinic of Navarra, School of Medicine, University of Navarra, Pamplona, Spain.
² Department of Dermatology, Reina Sofía University Hospital, Córdoba, Spain.
³ Department of Pathology, Reina Sofía University Hospital, Córdoba, Spain.

Rafael Salido-Vallejo et al. JAMA Dermatol. 2022.

. 2022 Jul 1;158(7):832-834.

doi: 10.1001/jamadermatol.2022.1278.

¹ Department of Dermatology, University Clinic of Navarra, School of Medicine, University of Navarra, Pamplona, Spain.
² Department of Dermatology, Reina Sofía University Hospital, Córdoba, Spain.
³ Department of Pathology, Reina Sofía University Hospital, Córdoba, Spain.

No abstract available

Comment in

SOX18 Targeting as a Potential, Viable Therapeutic Avenue for Kaposi Sarcoma.
Ojala PM, Francoís M. Ojala PM, et al. JAMA Dermatol. 2022 Dec 1;158(12):1458-1459. doi: 10.1001/jamadermatol.2022.4341. JAMA Dermatol. 2022. PMID: 36223085 No abstract available.
SOX18 Targeting as a Potential, Viable Therapeutic Avenue for Kaposi Sarcoma-Reply.
Salido-Vallejo R, España A. Salido-Vallejo R, et al. JAMA Dermatol. 2022 Dec 1;158(12):1459-1460. doi: 10.1001/jamadermatol.2022.4332. JAMA Dermatol. 2022. PMID: 36223092 No abstract available.